1. Walther G, Wagner L, Kurzai O. Updates on the taxonomy of Mucorales with an emphasis on clinically important taxa. J Fungi 2019; 5:106.
2. Kwon-Chung KJ. Taxonomy of fungi causing mucormycosis and entomophthoramycosis (zygomycosis) and nomenclature of the disease: molecular mycology perspectives. Clin Infect Dis
2012; 54 (suppl 1): S8-S15.
3. de Hoog GS, Guarro J, Gene F, et al. Atlas of Clinical Fungi. 4th ed. Hilversum: Atlas of Clinical Fungi, 2020.
4. Wijayawardene NN, Pawłowska J, Letcher PM, et al. Notes for genera: basal clades of fungi (including Aphelidiomycota, Basidiobolomycota, Blastocladiomycota, Calcarisporiellomycota,
Caulochytriomycota, Chytridiomycota, Entomophthoromycota, Glomeromycota, Kickxellomycota, Monoblepharomycota, MortierellomycotaMucoromycota, Neocallimastigomycota, Olpi-
diomycota, Rozellomycota and Zoopagomycota). Fungal Divers 2018; 92:43–129.
5. Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005; 41:634-653.
6. Gomes MZ, Lewis RE, Kontoyiannis DP. Mucormycosis caused by unusual mucormycetes, non-Rhizopus, -Mucor, and- Lichthemia species. Clin Microbiol Rev 2011; 24:411-445.
7. Bongomin F, Gago S, Oladel RO, Denning DW. Global and multi-national prevalence of fungal diseases—estimate precision. J Fungi 2017; 3:57.
8. Petrikkos G, Skiada A, Lortholary O, et al. Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis 2012; 54(suppl 1):S23-S34.
9. Pappas PG, Alexander BD, Andes DR, et al. Invasive fungal infections among organ transplant recipients, 2001-2006: overview of the Transplant Associated Infection Surveillance Network
(TRANSNET) database. Clin Infec Dis 2010; 50:1101-1111.
10. Bitar D, Che D. Epidemiology of mucormycosis in metropolitan France, 1997-2010. Med Sci (Paris) 2013; 29 Spec No 1: 7-12.
11. Dolatabadi S, Ahmadi B, Rezaei-Matehkolaei A, et al. Mucormycosis in Iran: A six-year retrospective experience. J Mycol Med 2018; 28: 269-73.
12. Prakash H, Arunaloke Chakrabarti A. Global epidemiology of mucormycosis. J. Fungi 2019; 5:26.
13. Cornely OA, Alastruey-Izquierdo A, Arenz D, et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology
in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis 2019; 19: e405-e421.
14. Cheng VCC, Chen JHK, Wong SCY, et al. Hospital outbreak of pulmonary and cutaneous zygomycosis due to contaminated linen otems from substandard laundry. Clin Infect Dis 2016;
62:714–721.
15. Sundermann AJ, Clancy CJ, Pasculle AW, et al. How clean is the linen at my hospital? The Mucorales on unclean linen discovery study of large United States transplant and cancer centers. Clin
Infect Dis 2019; 68:850–853.
16. Sen M, Honavar SG, Bansal R, et al. Epidemiology, clinical profile, management, and outcome of COVID-19-associated rhino-orbital- cerebral mucormycosis in 2826 patients in India—Col-
laborative OPAI-IJO Study on Mucormycosis in COVID-19 (COSMIC), Report 1. Indian J Ophthalmol 2021; 69:1670–1692.
17. Badali H, Cañete-Gibas C, McCarthy D, et al. Epidemiology and antifungal susceptibilities of mucoralean fungi in clinical samples from the United States. J Clin Microbiol 2021; 59: e01230-
21.
18. Guinea J, Escribano P, Vena A, et al. Increasing incidence of mucormycosis in a large Spanish hospital from 2007 to 2015: Epidemiology and microbiological characterization of the isolates.
PLoS One 2017; 12: e0179136.
19. Kontoyiannis DR, Lewis RE. Agents of mucormycosis and entomophthoramycosis. In: Bennett JE, Dolin R, Blaser MJ (eds). Principles and Practice of Infectious Diseases. Philadelphia:
Elsevier Churchill Livingstone, 2015: 2909-2919.
20. Doğulu S, Yardım M, Tezok OF, Gülşen M, Akkaya A. Cerebral mucormycosis. Bulletin of Gülhane Military Academy 1966; 9:219-222.
21. Demirkaya MH, Aslan H, Şehnaz A, et al. Mucormycosis in Turkey. Transplantation 2018; 102: 666.
22. Alabaz D, Yılmaz G, Uğuz A, Özdemir S, Şaşmaz İ, Bayram İ. Mucormycosis in a pediatric population: a review of 20 cases from southern Turkey. Turkish Journal of Pediatrics 2021; 63:11-22.
23. Yıldıran ŞT, Saraçlı MA, Gönlüm A, Haznedaroğlu T. Rhizopus oryzae’nın neden olduğu ölümcül rino-orbito-serebral zigomikoz olgusu. İnfeksiyon Dergisi 1999; 13:427-431.
24. Kasapoğlu F, Coşkun H, Özmen ÖA, Akalın H, Ener B. Acute invasive fungal rhinosinusitis: Evaluation of 26 patients treated with endonasal or open surgical procedures. Otolaryngology–
Head and Neck Surgery 2010; 143:614-620.
25. Kazak E, Aslan E, Akalın H, et al. A mucormycosis case treated with a combination of caspofungin and amphotericin B. Journal de Mycologie Médicale 2013; 23:179—184.
26. Liu M, Spellberg B, Phan QT, et al. The endothelial cell reseptör GRP78 is required for mucormycosis pathogenesis in diabetic mice. J Clin Invest 2010; 120:1914-1924.
27. Eucker J, Sezer O, Graf B, Possinger K. Mucormycoses. Mycoses 2001; 44: 253-260.
28. Waldorf AR, Lewitz SM, Diamond RD. In vivo bronchoalveolar macrophage defense aginst Rhizopus oryzae and Aspergillus fumigatus. J Infect Dis 1984; 150: 752-757.
29. Cornely OA, Arıkan-Akdağlı S, Dannaoui E, et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clin Microbiol Infect 2014; 20
(Suppl. 3): S5–S26.
30. Lass-Florl C, Resch G, Nachbaur D et al. The value of computed tomography-guided percutaneous lung biopsy for diagnosis of invasive fungal infection in immunocompromised patients.
Clin Infect Dis 2007; 45: e101–e104.
31. Lackner, M.; Caramalho, R.; Lass-Flörl, C. Laboratory diagnosis of mucormycosis: Current status and future perspectives. Future Microbiol. 2014, 9, 683–695.
32. Vaezi A, Fakhim H, Ilkit M, Faeli L, et al. Rapid and low-cost culture-based method for diagnosis of mucormycosis using a mouse model. Front Microbiol 2020; 11:440.
33. Skiada A, Lanternier F, Groll AH, et al. Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in
Leukemia (ECIL 3). Haematologica 2013; 98:492-504.
34. Lackner N, Posch W, Lass-Flörl C. Microbiological and molecular diagnosis of mucormycosis: from old to new. Microorganisms 2021, 9:1518.
35. Chowdhary A, Kathuria S, Singh PK, et al. Molecular characterization and in vitro antifungal susceptibility of 80 clinical isolates of mucormycetes in Delhi, India. Mycoses 2014; 57 Suppl 3:
97-107.
36. Balajee SA, Borman AM, Brandt ME, et al. Sequence-based identification of Aspergillus, Fusarium, and mucorales species in the clinical mycology laboratory: where are we and where should
we go from here? J Clin Microbiol 2009; 47: 877-84.
37. CLSI. Interpretive criteria for bacteria and fungi identification by DNA target sequencing; Approved Guideline MM-18A. Wayne, PA: Clinical and Laboratory Standards Institute, 2008.
38. Schwarz P, Lortholary O, Dromer F, Dannaoui E. Carbon assimilation profiles as a tool for identification of zygomycetes. J Clin Microbiol 2007; 45:1433–1439.
39. Shao J, Wan Z, Li R, Yu J. Species identification and delineation of pathogenic Mucorales by matrix-assisted laser desorption ionization–time of flight mass spectrometry. J Clin Microbiol
2018; 56: e01886-17.
40. Arendrup MC, Guinea J, Cuenca-Estrella M, et al. EUCAST DEFINITIVE DOCUMENT E.DEF 9.3: Method for the determination of broth dilution minimum inhibitory concentrations of
antifungal agents for conidia forming moulds. 2015.
41. CLSI. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. 3rd ed. CLSI Standard M38. Wayne, PA: Clinical and Laboratory Standards Institute; 2017.
42. Espinel-Ingroff A, Chakrabarti A, Chowdhary A, et al. Multicenter evaluation of MIC distributions for epidemiologic cutoff value definition to detect amphotericin B, posaconazole, and
itraconazole resistance among the most clinically relevant species of Mucorales. AAC 2015; 59:1745–1750.
43. Jensen HE, Salonen J, Ekfors TO. The use of immunohistochemistry to improve sensitivity and specificity in the diagnosis of systemic mycoses in patients with haematological malignancies.
J Pathol 1997; 181:100-105.
44. Marty FM, Ostrosky-Zeichner L, Cornely OA, et al. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. Lancet Infect Dis 2016;16: 828–37.
45. Roilides E, Antachopoulos C. Isavuconazole: an azole active against mucormycosis. Lancet Infect Dis 2016; 16: 761–62.
46. Jenks JD, Reed SL, Seidel D, et al. Rare mold infections caused by Mucorales, Lomentospora prolificans and Fusarium, San Diego: the role of antifungal combination therapy. Int J Antimicrob
Agents 2018; 52: 706–12.
47. Kyvernitakis A, Torres HA, Jiang Y, Chamilos G, Lewis RE, Kontoyiannis DP. Initial use of combination treatment does not impact survival of 106 patients with haematologic malignancies
and mucormycosis: a propensity score analysis. Clin Microbiol Infect 2016; 22: 811.
48. Wollenweber HW, Reinking OA. The Fusaria: Their description injurious effects and control. Paul Parey Berlin 1935; 8: 1–135.
49. Mikami R, Stemmermann GN. Keratomycosis caused by Fusarium oxysporum. Am J Clin Pathol 1958; 29: 257–262.
50. Al-Hatmi AM, Hagen F, Menken SB, Meis JF, de Hoog GS. Global molecular epidemiology and genetic diversity of Fusarium, a significant emerging group of human opportunists from. Emerg
Microbes Infect 2016; 5: e124.
51. de Hoog GS, Guarro J, Gené J, et al. Atlas of clinical fungi. 4th web-ed. Westerdijk Institute, Utrecht and Universitat Rovira i Virgili, Reus; 2019.
52. Alastruey-Izquierdo A, Alcazar-Fuoli L, Rivero-Menéndez O, et al. Molecular identification and susceptibility testing of molds isolated in a prospective surveillance of triazole resistance in
Spain (FILPOP2 study). Antimicrob Agents Chemother 2018; 62: e00358-18.
53. Kadaifciler DG, Demirel R. Fungal contaminants in man-made water systems connected to municipal water. J Water Health 2018; 16: 244–252.
54. Chang DC, Grant GB, Donnell KO, et al. Multistate Outbreak of Fusarium of a Contact Lens Solution. J Am Med Assoc 2006; 296: 953–963.
55. Sáenz V, Alvarez-Moreno C, Pape PL, Restrepo S, Guarro J, Ramírez AMC. A one health perspective to recognize Fusarium as important in clinical practice. JoF 2020; 6: 235.
56. Walther G, Stasch S, Kaerger K, et al. Fusarium keratitis in Germany. J Clin Microbiol 2017; 55: 2983–2995.
57. Crabol Y, Lortholary O. Invasive mold infections in solid organ transplant recipients. Scientifica 2014; 2014: 821969.
58. Herkert PF, Al-Hatmi AMS, de Oliveira Salvador GL, et al. Molecular characterization and antifungal susceptibility of clinical Fusarium species from Brazil. Front Microbiol 2019, 10:737.
59. da Rosa PD, Aquino V, Fuentefria AM, Goldani LZ. Diversity of Fusarium species causing invasive and disseminated infections. J Mycol Med 2021; 31: 101137.
60. Tortorano AM, Prigitano A, Esposto MC, et al. European confederation of medical mycology (ECMM) epidemiological survey on invasive infections due to Fusarium species in Europe. Eur
J Clin Microbiol Infect Dis 2014; 33: 1623–1630.
61. Dalyan Cilo B, Al Hatmi AM, Seyedmousavi S, et al. Emergence of fusarioses in a university hospital in Turkey during a 20-year period. Eur J Clin Microbiol Infect Dis 2015; 34(8): 1683-1691.
62. van Diepeningen AD, Feng P, Ahmed S, Sudhadham M, Bunyaratavej S, de Hoog GS. Spectrum of Fusarium infec tions in tropical dermatology evidenced by multilocus sequencing typing
diagnostics. Mycoses 2015; 58(1):48–57.
63. Lortholary O, Obenga G, Biswas P, et al. International retrospective analysis of 73 cases of invasive fusariosis treated with voriconazole. Antimicrob Agents Chemother 2010; 54: 4446–4450.
64. Shoham S, Levitz SM. The immune response to fungal infections. Br J Haematol 2005; 129: 569–582.
65. Winn RM, Gil-Lamaignere C, Maloukou A, Roilides E, Network E. Interactions of human phagocytes with moulds Fusarium spp. and Verticillium nigrescens possessing different pathogeni-
city. Med Mycol 2003; 41: 503–509.
66. Khan Z, Ahmad S, Alfouzan W, Joseph L, Varghese S. Demonstration of adventitious Sporulation in Fusarium petroliphilum Onychomycosis. Mycopathologia 2019; 184: 303–308.
67. Nucci M, Anaissie E. Invasive fusariosis. Clin Microbiol Rev 2023: 36(4): e0015922.
68. Nucci M, Varon AG, Garnica M, et al. Increased incidence of invasive fusariosis with cutaneous portal of entry, Brazil. Emerg Infect Dis 2013; 19: 1567–1572.
69. Kredics L, Narendran V, Shobana CS, Vágvölgyi C, Manikandan P; Indo-Hungarian Fungal Keratitis Working Group. Filamentous fungal infections of the cornea: a global overview of epide-
miology and drug sensitivity. Mycoses 2015; 58: 243–260
70. Nucci M, Marr KA, Vehreschild M, et al. Improvement in the outcome of invasive fusariosis in the last decade. Clin Microbiol Infect 2014; 20: 580–585.
71. Campo M, Lewis RE, Kontoyiannis DP. Invasive fusariosis in patients with hematologic malignancies at a cancer center: 1998–2009. J Infect 2010; 60: 331–337.
72. Nucci M, Anaissie E. Cutaneous infection by Fusarium species in healthy and immunocompromised hosts: implications for diagnosis and management. Clin Infect Dis 2002; 35: 909–920.
73. O’Donnell K, Sutton DA, Rinaldi MG et al. Internet-accessible DNA sequence database for identifying fusaria from human and animal infections. J Clin Microbiol 2010; 48: 3708–3718.
74. De Carolis E, Posteraro B, Lass-Flo¨rl C et al. Species identification of Aspergillus, Fusarium and Mucorales with direct surface analysis by matrix-assisted laser desorption ionization ti-
me-of-flight mass spec trometry. Clin Microbiol Infect 2012; 18: 475–484.
75. Odabasi Z, Mattiuzzi G, Estey E et al. b-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous
leukemia and myelodysplastic syndrome. Clin Infect Dis 2004; 39: 199–205.
76. Tortorano AM, Esposto MC, Prigitano A, et al. Cross-reactivity of Fusarium spp. in the Aspergillus galactomannan enzyme-linked immu nosorbent assay. J Clin Microbiol 2011; 50: 1051–
1053.
77. Pfaller MA, Carvalhaes CG, Rhomberg P, Messer SA, Castanheira M. Antifungal susceptibilities of opportunistic filamentous fungal pathogens from the Asia and western Pacific region: data
from the SENTRY antifungal surveillance program. J Antibiot 2021; 74:519–527.
78. Hoenigl M, Salmanton-García J, Walsh TJ, et al. Global guideline for the diagnosis and management of rare mould infectionsan initiative of the European confederation of medical mycology
in cooperation with the international society for human and animal mycology and the American society for microbiology. Lancet Infect Dis 2021; 21: e246–e257.
79. Ghannoum M, Isham N. Fungal nail infections (Onychomycosis): A never-ending story? PLoS Pathog 2014; 10(6): e1004105.
80. Maertens JA, Girmenia C, Brüggemann RJ, et al. European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the
European conference on infections in leukaemia. J Antimicrob Chemother 2018; 73: 3221–3230.
81. Ramirez-Garcia A, Pellon A, Rementeria A, et al. Scedosporium and Lomentospora: An updated overview of underrated opportunists. Med Mycol 2018; 56: 102–125.
82. Biswas C, Law D, Birch M, et al. In vitro activity of the novel antifungal compound F901318 against Australian Scedosporium and Lomentospora fungi. Med Mycol 2018; 56: 1050–1054.
83. Mcneill J, Barrie FR, Buck WR, eds. International Code of Nomenclature for Algae, Fungi, and Plants (Melbourne Code). Regnum Vegetabile 154. Oberreifenberg: Germany: Koeltz Sci Books,
2012.
84. Bronnimann D, Garcia-Hermoso D, Dromer F, Lanternier F. Scedosporiosis/lomentosporiosis observational study (SOS): Clinical significance of Scedosporium species identification. Med
Mycol 2021; 59(5):486-497.
85. Pham T, Giraud S, Schuliar G, Rougeron A, Bouchara JP. Scedo-Select III: A new semi-selective culture medium for detection of the Scedosporium apiospermum species complex. Med Mycol
2015; 53: 512–519.
86. Delhaes L, Harun A, Chen SCA et al. Molecular typing of Australian Scedosporium isolates showing genetic variability and numerous S. aurantiacum. Emerg Infect Dis. 2008; 14: 282–290.
87. Song MJ, Lee JH, Lee NY. Fatal Scedosporium prolificans infection in a paediatric patient with acute lymphoblastic leukaemia. Mycoses 2011; 54: 81–83.
88. Nakamura Y, Suzuki N, Nakajima Y et al. Scedosporium aurantiacum brain abscess after near-drowning in a survivor of a tsunami in Japan. Respir Investig 2013; 51: 207–211.
89. Seidel D, Meißner A, Lackner M, et al. Prognostic factors in 264 adults with invasive Scedosporium spp. and Lomentospora prolificans infection reported in the literature and FungiScope. Crit
Rev Microbiol 2019; 45: 1–21.
90. Chen TC, Ho MW, Chien WC, Lin HH. Disseminated Scedosporium apiospermum infection in a near-drowning patient. J Formos Med Assoc 2016; 115: 213–14.
91. Shimizu J, Yoshimoto M, Takebayashi T, Ida K, Tanimoto K, Yamashita T. Atypical fungal vertebral osteomyelitis in a tsunami survivor of the Great East Japan Earthquake. Spine 2014; 39:
e739–42.
92. Pang KR, Wu JJ, Huang DB, Tyring SK. Subcutaneous fungal infections. Dermatol Ther 2004; 17: 523–31.
93. Schwarz C, Brandt C, Melichar V, et al. Combined antifungal therapy is superior to monotherapy in pulmonary scedosporiosis in cystic fibrosis. J Cyst Fibros 2019; 18: 227–232.
94. Chen SCA, Halliday CL, Hoenigl M, Cornely OA, Meyer W. Scedosporium and Lomentospora infections: contemporary microbiological tools for the diagnosis of invasive disease. J Fungi
2021; 7:23.
95. Tortorano AM, Richardson M, Roilides E et al. ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: Fusarium spp., Scedosporium spp. and others. Clin
Microbiol Infect 2014; 20: 27–46.
96. Hennebert BJ, Desai BG. Lomentospora prolificans, a new hyphomycete from greenhouse soil. Mycotaxon 1974; 1: 45–50.
97. Malloch D, Salkin I. A new species of Scedosporium associated with osteomyelitis in humans [Scedosporium inglatum, isolated from a bone biopsy]. Mycotaxon 1984; 21: 247–255.
98. Gueho E. Taxonomy of the medical species of Pseudallescheria and Scedosporium. J Mycol Med 1991; 118: 3–9.
99. Sedlacek L, Graf B, Schwarz C, et al. Prevalence of Scedosporium species and Lomentospora prolificans in patients with cystic fibrosis in a multicenter trial by use of a selective medium. J Cyst
Fibros 2015; 14: 237–41.
100. Lackner M, Rezusta A, Villuendas MC, Palacian MP, Meis F, Klaassen CH. Infection and colonisation due to Scedosporium in Northern Spain. An in vitro antifungal susceptibility and mole-
cular epidemiology study of 60 isolates. Mycoses 2011; 54: 12–21.
101. Caira M, Girmenia C, Valentini CG, et al. Scedosporiosis in patients with acute leukemia: A retrospective multicenter report. Haematologica 2008; 93: 104–110.
102. Cortez KJ, Roilides E, Quiroz-Telles F, et al. Infections caused by Scedosporium spp. Clin Microbiol Rev 2008; 21; 157–197.
103. Mello TP, Aor AC, Oliveira SS, Branquinha MH, Santos AL. Conidial germination in Scedosporium apiospermum, S. aurantiacum, S. minutisporum and Lomentospora prolificans: Influence of
growth conditions and antifungal susceptibility profiles. Mem Inst Oswaldo Cruz 2016; 111: 484–494.
104. Kauffman CA. Fungal infections. Proc Am Thorac Soc 2006; 3: 35–40.
105. Buldain I, Martin-Souto L, Antoran A, et al. The Host Immune Response to Scedosporium/Lomentospora. J Fungi 2021; 7: 75.
106. Seidel D, Hassler A, Salmanton-Garcia J, Koehler P, et al. Invasive Scedosporium spp. and Lomentospora prolificans infections in pediatric patients: Analysis of 55 cases from FungiScope(R)
and the literature. Int J Infect Dis 2020; 92: 114–122.
107. Jenks JD, Seidel D, Cornely OA, et al. Clinical characteristics and outcomes of invasive Lomentospora prolificans infections: Analysis of patients in the FungiScope((R)) registry. Mycoses 2020;
63: 437–442.
108. Tamaki M, Nozaki K, Onishi M, Yamamoto K, Ujiie H, Sugahara H. Fungal meningitis caused by Lomentospora prolificans after allogeneic hematopoietic stem cell transplantation. Transpl
Infect Dis 2016; 18: 601–605.
109. Kelly M, Stevens R, Konecny P. Lomentospora prolificans endocarditis—Case report and literature review. BMC Infect Dis 2016; 16: 36.
110. Vazirani J, Westall GP, Snell GI, Morrissey CO. Scedosporium apiospermum and Lomentospora prolificans in lung transplant patients—A single center experience over 24 years. Transpl Infect
Dis 2021; 23: e13546.
111. Cobo F, Lara-Oya A, Rodriguez-Granger J, Sampedro A, Aliaga-Martinez L, Navarro-Mari JM. Infections caused by Scedosporium/Lomentospora species: Clinical and microbiological findings
in 21 cases. Med Mycol 2018; 56: 917–925.
112. Rodriguez-Tudela JL, Berenguer J, Guarro J, et al. Epidemiology and outcome of Scedosporium prolificans infection, a review of 162 cases. Med Mycol 2009; 47: 359–370.
113. Mcguire TW, Bullock JD, Bullock JD, Jr. Elder BL, Funkhouser JW. Fungal endophthalmitis. An experimental study with a review of 17 human ocular cases. Arch Ophthalmol 1991; 109:
1289–1296.
114. Wood GM, McCormack JG, Muir DB, et al. Clinical features of human infection with Scedosporium inflatum. Clin Infect Dis 1992; 14: 1027–1033.
115. Wen SC, Phillips D, Gwee A. Scedosporium prolificans Otitis Externa. Pediatr Infect Dis J 2016; 35: 1277.
116. Kimura M, Maenishi O, Ito H, Ohkusu K. Unique histological characteristics of Scedosporium that could aid in its identification. Pathol Int 2010; 60: 131–136.
117. Cuenca-Estrella M, Bassetti M, Lass-Florl C, Racil Z, Richardson M, Rogers TR. Detection and investigation of invasive mould disease. J Antimicrob Chemother 2011; 66: 15–24.
118. Donnelly JP, Chen SC, Kauffman CA, et al. Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of
Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis 2020; 71: 1367–1376.
119. Buitrago MJ, Bernal-Martinez L, Castelli MV, Rodriguez-Tudela JL, Cuenca-Estrella M. Performance of panfungal- and specific-PCR-based procedures for etiological diagnosis of invasive
fungal diseases on tissue biopsy specimens with proven infection: A 7-year retrospective analysis from a reference laboratory. J Clin Microbiol 2014; 52: 1737–1740.
120. Wilkendorf LS, Bowles E, Buil J, et al. Update on Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry Identification of Filamentous Fungi. J Clin Microbiol 2020;
58: e01263-20.
121. Feldman R, Cockerham L, Buchan BW et al. Treatment of Paecilomyces variotii pneumonia with posaconazole: case report and literature review. Mycoses 2016; 59: 746–50.,
122. Barker AP, Horan JL, Slechta ES et al. Complexities associated with the molecular and proteomic identification of Paecilomyces species in the clinical mycology laboratory. Med Mycol 2014;
52: 537–545.
123. Larone DH, eds. Medically Important Fungi: A Guide to Identification. 5th Edition. ASM Press, 2013.
124. Pastor FJ, Guarro J. Clinical manifestations, treatment and outcome of Paecilomyces lilacinus infections. Clin Microbiol Infect 2006; 12: 948–960.
125. Urquhart AS, Mondo SJ, Ma¨kela¨ MR, et al. Genomic and genetic insights into a cosmopolitan fungus, Paecilomyces variotii (Eurotiales). Front Microbiol 2018; 9: 3058
126. Torres R, Gonzalez M, Sanhueza M et al. Outbreak of Paecilomyces variotii peritonitis in peritoneal dialysis patients after the 2010 Chilean earthquake. Perit Dial Int 2014; 34: 322–325.
127. Sprute R, Salmanton-García J, Sal E, et al. Characterization and outcome of invasive infections due to Paecilomyces variotii: Analysis of patients from the FungiScope® registry and literature reports.
J Antimicrob. Chemother 2021; 76: 765–774.
128. Gülmez D. Ülkemizde nadir küf mantarlarına bağlı mikozlar: sistematik bir derleme. Mikrobiyol Bul 2022; 56: 143-189.
129. Mikami Y, Fukushima K, Arai T, et al. Leucinostatins, peptide mycotoxins produced by Paecilomyces lilacinus and their possible roles in fungal infection. Zentralbl Bakteriol Mikrobiol Hyg
1984; 257: 275-283.
130. Liu K, Howell DN, Perfect JR, Schell WA. Morphologic criteria for the preliminary identification of Fusarium, Paecilomyces, and Acremonium species by histopathology. Am J Clin Pathol 1998;
109: 45-54.
131. Chen WY, Lin SR, Hung SJ. Successful Treatment of Recurrent Cutaneous Purpureocillium lilacinum (Paecilomyces lilacinus) Infection with Posaconazole and Surgical Debridement. Acta
Derm Venereol 2019; 99: 1313–1314.
132. Marques DP, Carvalho J, Rocha S, et al. A case of pulmonary mycetoma caused by Paecilomyces variotii. Eur J Case Rep Intern Med 2019; 6: 001040.
133. Luangsa-Ard J, Houbraken J, van Doorn T, et al. Purpureocillium, a new genus for the medically important Paecilomyces lilacinus. FEMS Microbiol Lett 2011; 321: 141–149.
134. Itin PH, Frei R, Lautenschlager S, et al. Cutaneous manifestations of Paecilomyces lilacinus infection induced by a contaminated skin lotion in patients who are severely immunosuppressed. J
Am Acad Dermatol 1998; 39: 401–409.
135. Sprute R, Salmanton-García J, Sal E, et al. Invasive infections with Purpureocillium lilacinum: Clinical characteristics and outcome of 101 cases from FungiScope® and the literature. J Antimic-
rob Chemother 2021; 7: 1593–1603.
136. Saghrouni F, Saidi W, Ben Said Z, et al. Cutaneous hyalohyphomycosis caused by Purpureocillium lilacinum in an immunocompetent patient: Case report and review. Med Mycol 2013; 51:
664–668.
137. Trinh SA, Angarone MP. Purpureocillium lilacinum tattoo-related skin infection in a kidney transplant recipient. Transpl Infect Dis 2017; 19: e12689.
138. Anaissie EJ, Stratton SL, Dignani MC, et al. Pathogenic molds (including Aspergillus species) in hospital water distribution systems: a 3-year prospective study and clinical implications for
patients with hematologic malignancies. Blood 2003; 101: 2542–2546.
139. Lockwood MB, Crescencio JC. Adventitious sporulation in Fusarium: The yeast that were not. IDCases 2015; 3: 5–7.
140. Albert R, Lemaignen A, Desoubeaux G, Bailly E, Bernard L, Lacasse M. Chronic subcutaneous infection of Purpureocillium lilacinum in an immunocompromised patient: Case report and
review of the literature. Med Mycol Case Rep 2022; 38: 5–8.
141. Accetta J, Powell E, Boh E, Bull L, Kadi A, Luk A. Isavuconazonium for the treatment of Purpureocillium lilacinum infection in a patient with pyoderma gangrenosum. Med Mycol Case Rep
2020; 29: 18–21.
142. DiSalvo AF, Fickling AM, Ajello L. Infection caused by Penicillium marneffei: Description of first natural infection in man. Am J Clin Patho 1973; 60: 259–263
143. Xia XJ, Shen H, Xu AE. Cutaneous Penicillium marneffei infection in a patient with idiopathic CD4(+) lymphocytopenia. J Dermatol 2015; 42: 812–814.
144. Cao L, Chen DL, Lee C, ET AL. Detection of specific antibodies to an antigenic mannoprotein for diagnosis of Penicillium marneffei penicilliosis. J Clin Microbiol 1998; 36: 3028–3031.
145. Vossler J. Penicillium marneffei: An emerging fungal pathogen. Clinical Microbiology 2001; 23: 25-29.
146. Chan JF, Lau SK, Yuen KY, Woo PC. Talaromyces (Penicillium) marneffei infection in non-HIV-infected patients. Emerging Microbes Infection 2016; 5: e19.
147. Karo FA, Kembaren T, Saragih R, Sembiring E, Ginting F. Cutaneous penicilliosis due to Penicillium marneffei infection in human immunodeficiency virus infected patients. IOP Conf Ser
Earth Environ Sci 2018; 12: 012060.
148. Chitasombat M, Supparatpinyo K. Penicillium marneffei Infection in Immunocompromised Host. Curr Fungal Infect Rep 2013; 7: 44–50.
149. Youngchim S. Talaromyces marneffei Infection: Virulence Factors and Rapid Diagnostics. In: Garbacz K, Jarzembowski T, Ran Y, Samie A, Saxena SK, eds. Infectious Diseases Annual Volume.
İntechOpen; 2022.
150. Le T, Farrar J, Shikuma C. Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: Implications for eradication. AIDS 2011;
25: 871-872.
151. Qin L, Zhao L, Tan C, Chen XU, Yan Z, Mo W. A novel method of combining Periodic Acid Schiff staining with Wright-Giemsa staining to identify the pathogens Penicillium marneffei, His-
toplasma capsulatum, Mucor and Leishmania donovani in bone marrow smears. Exp Ther Med 2015; 9: 1950–1954.
152. Supparatpinyo K, Khamwan C, Baosoung V, Nelson KE, Sirisanthana T. Disseminated Penicillium marneffei infection in Southeast Asia. Lancet 1994; 344: 110-113.
153. Kaplan JE, Benson C, Holmes KK, Brooks JT, Pa A, Masur H. Centers for Disease Control and Prevention (CDC); National Institutes of Health; HIV Medicine Association of the Infectious
Diseases Society of America. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: Recommendations from CDC, the National Institu-
tes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recommend Rep 2009; 58: 1–207.
154. Lang Q, Pasheed Chughtai A, Kong WF, Yan HY. Case Report: Successful Treatment of Pulmonary Talaromyces vmarneffei Infection with Posaconazole in a Renal Transplant Recipient. Am J
Trop Med Hyg 2020; 104: 744–747.
155. Li L, Chen K, Dhungana N, Jang Y, Chaturvedi V, Desmond E. Characterization of Clinical Isolates of Talaromyces marneffei and Related Species, California, USA. Emerg Infect Dis 2019; 25:
1765–1768.
156. Grant DC, Sutton DA, Sandberg CA, et al. Disseminated Geosmithia argillacea infection in a German shepherd dog. Med Mycol 2009; 47: 221–226.
157. Houbraken J, Giraud S, Meijer M, et al. Taxonomy and antifungal susceptibility of clinically important Rasamsonia species. J Clin Microbiol 2013; 51: 22–30.
158. Houbraken J, Spierenburg H, Frisvad JC. Rasamsonia, a new genus comprising thermotolerant and thermophilic Talaromyces and Geosmithia species. Antonie Van Leeuwenhoek 2012; 101:
403–421.
159. Stemler J, Salmanton-Garcia J, Seidel D, et al. Risk factors and mortality in invasive Rasamsonia spp infection: analysis of cases in the FungiScope registry and from the literature. Mycoses
2020; 63: 265-274.
160. Reiss E, Shadomy HJ, Lyon GM. Fundamental Medical Mycology, New Jersey: Wiley-Blackwell; 2012: 215-232.
161. Pérez-Cantero, A, Guarro J. Current knowledge on the etiology and epidemiology of Scopulariopsis infections. Med Mycol 2020; 58: 145–155.
162. Aydın S, Ertuğrul B, Gültekin B, Uyar G, Kır E. Treatment of two postoperative endophthalmitis cases due to Aspergillus flavus and Scopulariopsis spp. with local and systemic antifungal
therapy. BMC Infect Dis 2007; 7:87.
163. Tikveşli M, Garip R, Solak M, Kaya Ö, Güdücüoğlu H. Scopulariopsis brevicaulis’in neden olduğu fungal keratit olgusu. Turk Mikrobiyol Cemiy Derg 2024; 54: 68-71.
164. Filipello Marchisio V, Fusconi A, Querio FL. Scopulariopsis brevicaulis: a keratinophilic or a keratinolytic fungus? Mycoses 2000; 43: 281-92.
165. Iwen PC, Schutte SD, Florescu DF, Noel-Hurst RK, Sigler L. Invasive Scopulariopsis brevicaulis infection in an immunocompromised patient and review of prior cases caused by Scopulariopsis
and Microascus species. Mycoses 2012; 50: 561–569.
166. Ng KP, Soo-Hoo TS, Na SL, Gan GG, Sangkar JV, Teh AK. Scopulariopsis brevicaulis infection in a patient with acute myeloid leukemia. Med J Malaysia 2003; 58: 608–612.
167. Yang Q, Wei J, Chen Z. Fatal bronchial invasion of Scopulariopsis brevicaulis in an acute monocytic leukemia patient. Diagn Microbiol Infec Dis 2012; 73: 369–371.
168. Kurata K, Nishimura S, Ichikawa H, et al. Invasive Scopulariopsis alboflavescens infection in patient with acute myeloid leukemia. Int J Hematol 2018; 108: 658–664.
169. Gupta AK, Gregurek-Novak T. Efficacy of itraconazole, terbinafine, fluconazole, griseofulvin and ketoconazole in the treatment of Scopulariopsis brevicaulis causing onychomycosis of the toes.
Derma tology 2001; 202: 235–238.
170. Cavanna C, Pagella F, Esposto MC, et al. Human infections due to Schizophyllum commune: case report and review of the literature. J Mycol Med 2019; 29: 365–371.
171. Sigler L, de la Maza LM, Tan G, Egger KN, Sherburne RK. Diagnostic difficulties caused by a non-clamped Schizophyllum commune isolate in a case of fungus ball of the lung. J Clin Microbiol
1995; 33: 1979–1983.
172. Brandt ME. Filamentous basidiomycetes in the clinical labora tory. Curr Fungal Infect Rep 2013; 7: 219–223.
173. Chowdhary A, Randhawa HS, Gaur SN, et al. Schizophyllum commune as an emerging fungal pathogen: a review and report of two cases. Mycoses 2013; 56:1-10.
174. Chan JFW, Teng JLL, Li IWS, et al. Fatal empyema thoracis caused by Schizophyllum commune with cross-reactive cryptococcal antigenemia. J Clin Microbiol 2014; 52: 683–687.